Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

Video

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapies in multiple myeloma.

BCMA-targeted CAR T-cell therapy is a potent treatment strategy that provides another line of therapy to heavily pretreated patients, says Avigan. However, one has to be aware of the potential treatment-related adverse events (TRAEs), such as neurotoxicity and cytokine release syndrome. Generally, the TRAEs are manageable, but patients have to be monitored closely, nonetheless.

Although the modality has demonstrated high objective response rates in this patient population, they tend to drop off after the first year of treatment, explains Avigan. As such, there is a lot of ongoing work aimed at addressing patterns of resistance to CAR T-cell therapy in an attempt to improve upon T-cell persistence.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.